JPH08157436A - Benzoic acid amide derivative - Google Patents
Benzoic acid amide derivativeInfo
- Publication number
- JPH08157436A JPH08157436A JP30486994A JP30486994A JPH08157436A JP H08157436 A JPH08157436 A JP H08157436A JP 30486994 A JP30486994 A JP 30486994A JP 30486994 A JP30486994 A JP 30486994A JP H08157436 A JPH08157436 A JP H08157436A
- Authority
- JP
- Japan
- Prior art keywords
- group
- benzoic acid
- skin
- acid amide
- amide derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
(57)【要約】
【構成】 式(1)〔R1 はC8−C24ヒドロキシアル
キル基又は3,7,11−トリメチル−2,6,10−
ドデカトリエニル基、R2 及びR3 はH又は水酸基を有
していてもよいC1−C3アルキル基〕で表わされる安息
香酸アミド誘導体又はその塩。
【化1】
【効果】 この化合物はヒト皮膚の真皮に存在する線維
芽細胞のコラーゲン合成を促進させ、その結果、加齢や
紫外線照射によって生じるしわを改善するので皮膚外用
剤として有用である。(57) [Summary] [Structure] Formula (1) [R 1 is a C 8 -C 24 hydroxyalkyl group or 3,7,11-trimethyl-2,6,10-
Dodecatrienyl group, R 2 and R 3 are H or a C 1 -C 3 alkyl group which may have a hydroxyl group], or a benzoamide derivative or salt thereof. Embedded image [Effect] This compound promotes collagen synthesis of fibroblasts existing in the dermis of human skin, and as a result, improves wrinkles caused by aging and ultraviolet irradiation, and is therefore useful as a skin external preparation.
Description
【0001】[0001]
【産業上の利用分野】本発明は皮膚におけるコラーゲン
合成促進作用及びしわ改善作用を有し、皮膚化粧料の成
分として有用な安息香酸アミド誘導体又はその塩に関す
る。FIELD OF THE INVENTION The present invention relates to a benzoic acid amide derivative or a salt thereof having a collagen synthesis promoting action and a wrinkle improving action in the skin and useful as a component of skin cosmetics.
【0002】[0002]
【従来の技術】皮膚は表皮、真皮、皮下組織に分けられ
る。その中で真皮は結合組織として皮膚の支持、恒常性
維持等に重要な役割を果たしている。真皮では主に線維
芽細胞がコラーゲン、エラスチン、フィブロネクチン等
の線維状タンパクやヒアルロン酸などのグリコサミノグ
ルカンを産生し、これらが3次元的な構造を形成し、結
合組織を維持している。2. Description of the Related Art The skin is divided into epidermis, dermis and subcutaneous tissue. Among them, the dermis plays an important role as a connective tissue in supporting the skin and maintaining homeostasis. In the dermis, fibroblasts mainly produce fibrous proteins such as collagen, elastin and fibronectin and glycosaminoglucans such as hyaluronic acid, which form a three-dimensional structure and maintain connective tissue.
【0003】一方、加齢による老化や紫外線による光老
化に伴って生じる皮膚の形態的変化としてはまず皮膚の
厚さの減少、委縮などが挙げられる。次いで、弾性回復
力が低下し、やがて老人の皮膚にみられるような最も特
徴的な変化である、しわやたるみを形成するに至る(M
arks R.,Biochemistry andP
hysiology of the Skin,Oxf
ord Univ.Press,1983)。On the other hand, as the morphological changes of the skin caused by aging due to aging and photoaging due to ultraviolet rays, there are firstly a decrease in skin thickness and atrophy. Then, the elastic recovery decreases, and eventually wrinkles and sagging are formed, which are the most characteristic changes as seen in the skin of the aged (M
arks R.A. , Biochemistry and P
hyology of the Skin, Oxford
ord Univ. Press, 1983).
【0004】これらの事象を生化学的に観察すると、真
皮の老化に伴って生じる最も大きな生化学的変化は、結
合組織の主成分であるコラーゲンに認められる。皮膚に
おけるコラーゲンの量は20才から80才にかけてその
35%が失われ、真皮の厚さは減少する(Shuste
r S.,British Journal ofDe
rmatology,93,639(1975))。ま
た、コラーゲンの代謝も低下するため、コラーゲン線維
中に無秩序な分子間架橋構造(A.M.Kligma
n,加齢と皮膚,p.221(1986))や、糖化等
が進行し、非可溶性のコラーゲンは増加する(Legr
aed Y.,Pathological Biolo
gy,17,991(1969))。このような生化学
的変化が積み重なり、結合組織は硬化し、柔軟性、伸展
性を失い、それが皮膚のしわ等につながっていくものと
考えられている。When these events are observed biochemically, the greatest biochemical change that accompanies aging of the dermis is found in collagen, which is the main component of connective tissue. 35% of the amount of collagen in the skin is lost between the ages of 20 and 80, and the thickness of the dermis is reduced (Shuste
r S. , British Journal of De
rmatology, 93 , 639 (1975)). In addition, since the metabolism of collagen is also reduced, a disordered intermolecular crosslinked structure (AM Kligma) is present in collagen fibers.
n, aging and skin, p. 221 (1986)), saccharification, etc., and insoluble collagen increases (Legr
aed Y. , Pathological Biolo
gy, 17 , 991 (1969)). It is considered that such biochemical changes are accumulated, the connective tissue hardens, loses flexibility and extensibility, and leads to wrinkles of the skin.
【0005】これらの研究結果より、皮膚にコラーゲン
を供給するべく、コラーゲンを配合した化粧品が上市さ
れているが、皮膚表面に塗布されたコラーゲンは真皮組
織には充分量到達せず、しわ改善効果を得るには至って
いない。ところで、真皮線維芽細胞のコラーゲン合成を
特異的に亢進することができれば、減少していた真皮コ
ラーゲンを新生コラーゲンにより増加させ、更には、コ
ラーゲンの代謝回転も活性化され、新生された可溶性コ
ラーゲンが更に増加することになり、その結果、結合組
織の柔軟性、伸展性を改善し、しわに代表される皮膚老
化の形態的変化を改善できると考えられる。According to the results of these studies, cosmetics containing collagen have been put on the market to supply collagen to the skin, but the collagen applied to the skin surface does not reach the dermal tissue in a sufficient amount, and wrinkle improving effect is obtained. Has not come to get. By the way, if it is possible to specifically enhance the collagen synthesis of dermal fibroblasts, the decreased dermal collagen is increased by the new collagen, and further, the turnover of collagen is also activated, and the new soluble collagen is generated. It is further considered that as a result, the softness and extensibility of connective tissue can be improved, and the morphological changes of skin aging represented by wrinkles can be improved.
【0006】レチノイン酸はしわ改善剤として注目され
ている薬剤であるが、当該レチノイン酸によるしわ改善
作用とコラーゲン合成促進作用には相関性があることが
知られている(E.Schwartz et al,
J.Invest.Derm.96,975(199
1);F.Bryce et al,Photoder
matol.,190,352(1990);R.Ma
rks et al,British Journal
of Dermatology,122,91(19
90))。しかしながら、レチノイン酸は強い皮膚刺激
性や皮膚の肥厚、催奇形成等の副作用を有するため、一
般的な医薬、医薬部外品、化粧品などに配合することが
できない。[0006] Retinoic acid is a drug attracting attention as a wrinkle-improving agent, but it is known that there is a correlation between the wrinkle-improving action and the collagen synthesis promoting action of the retinoic acid (E. Schwartz et al.
J. Invest. Derm. 96 , 975 (199
1); Bryce et al, Photoder
matol. , 190 , 352 (1990); Ma
rks et al, British Journal
of Dermatology, 122 , 91 (19
90)). However, retinoic acid has side effects such as strong skin irritation, skin thickening, and teratogenicity, and therefore cannot be incorporated into general medicines, quasi drugs, cosmetics and the like.
【0007】また、コラーゲン合成を促進する物質とし
てはビタミンC類、1α,25−ジヒドロキシビタミン
D3 、丹参の根の抽出物、ホ乳動物の乳清(J.Dob
aket al,J.Dermatological
Science,8,18(1984);特開平2−2
9080号、特開平3−20206号)等が知られてい
るが、これらは経皮吸収性、安定性、効果などの点で未
だ充分満足できるものではない。[0007] As substances that promote collagen synthesis, vitamin Cs, 1α, 25-dihydroxyvitamin D 3 , Danshen root extract, milk whey from mammals (J. Dob).
aket al, J .; Dermatological
Science, 8 , 18 (1984); Japanese Patent Laid-Open No. 2-2
No. 9080, JP-A-3-20206) and the like are known, but they are not yet sufficiently satisfactory in terms of transdermal absorbability, stability, effect and the like.
【0008】[0008]
【発明が解決しようとする課題】従って本発明の目的
は、コラーゲン合成促進作用、しわ改善作用を有し、か
つ経皮吸収性、化学的安定性等の良好な新規化合物を提
供することにある。SUMMARY OF THE INVENTION Therefore, an object of the present invention is to provide a novel compound having a collagen synthesis promoting action, a wrinkle improving action, and good transdermal absorbability and chemical stability. .
【0009】[0009]
【課題を解決するための手段】そこで本発明者らは、種
々の化合物を合成し、そのヒト皮膚線維芽細胞のコラー
ゲン合成促進作用及びしわ改善作用のスクリーニングを
したところ、下記一般式(1)で表わされる安息香酸ア
ミド誘導体に優れたコラーゲン合成促進効果及びしわ改
善効果があることを見出し、本発明を完成するに至っ
た。Therefore, the present inventors synthesized various compounds and screened the human skin fibroblasts for their collagen synthesis promoting action and wrinkle improving action. The following general formula (1) It was found that the benzoic acid amide derivative represented by the following formula has an excellent effect of promoting collagen synthesis and an effect of improving wrinkles, and has completed the present invention.
【0010】すなわち、本発明は次の一般式(1)That is, the present invention has the following general formula (1):
【0011】[0011]
【化2】 Embedded image
【0012】〔式中、R1 は炭素数8〜24のヒドロキ
シアルキル基又は3,7,11−トリメチル−2,6,
10−ドデカトリエニル基を示し、R2 及びR3 はそれ
ぞれ水素原子又は水酸基が置換していてもよい炭素数1
〜3のアルキル基を示す〕で表わされる安息香酸アミド
誘導体又はその塩を提供するものである。[Wherein R 1 is a hydroxyalkyl group having 8 to 24 carbon atoms or 3,7,11-trimethyl-2,6,
A 10-dodecatrienyl group is shown, and R 2 and R 3 each have 1 carbon atom which may be replaced by a hydrogen atom or a hydroxyl group.
A benzoamide derivative or a salt thereof represented by
【0013】一般式(1)において、R1 で示される炭
素数8〜24のヒドロキシアルキル基には、直鎖、分岐
鎖又は環状のヒドロキシアルキル基が含まれる。In the general formula (1), the hydroxyalkyl group having 8 to 24 carbon atoms represented by R 1 includes a linear, branched or cyclic hydroxyalkyl group.
【0014】また、R1 で示されるヒドロキシアルキル
基の具体例としては、8−ヒドロキシオクチル基、10
−ヒドロキシデシル基、11−ヒドロキシウンデシル
基、12−ヒドロキシドデシル基、12−ヒドロキシオ
クタデシル基等が挙げられる。Specific examples of the hydroxyalkyl group represented by R 1 include 8-hydroxyoctyl group and 10
-Hydroxydecyl group, 11-hydroxyundecyl group, 12-hydroxydodecyl group, 12-hydroxyoctadecyl group and the like can be mentioned.
【0015】R2 及びR3 で示される水酸基が置換して
いてもよい炭素数1〜3のアルキル基としては、メチル
基、エチル基、n−プロピル基、イソプロピル基、ヒド
ロキシメチル基、2−ヒドロキシエチル基、3−ヒドロ
キシプロピル基等が挙げられる。The alkyl group having 1 to 3 carbon atoms which may be substituted by the hydroxyl group represented by R 2 and R 3 includes methyl group, ethyl group, n-propyl group, isopropyl group, hydroxymethyl group, 2- Examples thereof include hydroxyethyl group and 3-hydroxypropyl group.
【0016】一般式(1)において、−O−R1 で示さ
れる基はベンゼン環上の2−、3−又は4−位のいずれ
の位置に置換してもよいが、2−位又は4−位に置換す
るのが好ましく、特に4−位に置換するのが好ましい。In the general formula (1), the group represented by -O-R 1 may be substituted at any position of 2-, 3- or 4-position on the benzene ring, but it may be at 2-position or 4-position. Substitution at the -position is preferable, and substitution at the 4-position is particularly preferable.
【0017】安息香酸アミド誘導体(1)の塩として
は、薬学的に許容される塩であれば特に制限されず、例
えばナトリウム、カリウム等のアルカリ金属塩、カルシ
ウム、マグネシウム等のアルカリ土類金属塩、アンモニ
ウム塩、モノ−、ジ−又はトリ−アルカノールアミン
塩、リジン、アルギニン等の塩基性アミノ酸塩等が挙げ
られる。また、安息香酸アミド誘導体(1)には、立体
異性体が存在する場合があるが、本発明においては、い
ずれの立体異性体も、またその混合物も使用できる。The salt of the benzoic acid amide derivative (1) is not particularly limited as long as it is a pharmaceutically acceptable salt, and examples thereof include alkali metal salts such as sodium and potassium, and alkaline earth metal salts such as calcium and magnesium. , Ammonium salts, mono-, di- or tri-alkanolamine salts, basic amino acid salts such as lysine and arginine, and the like. Although the benzoic acid amide derivative (1) may have stereoisomers, any stereoisomer or a mixture thereof can be used in the present invention.
【0018】上記一般式(1)で表わされる安息香酸ア
ミド誘導体の好ましい具体例としては、4−〔(2E,
6E)−3,7,11−トリメチル−2,6,10−ド
デカトリエニルオキシ〕ベンズアミド、4−(12−ヒ
ドロキシドデシルオキシ)ベンズアミド、4−(12−
ヒドロキシオクタデシルオキシ)ベンズアミド、4−
(11−ヒドロキシウンデシルオキシ)ベンズアミド、
4−(10−ヒドロキシデシルオキシ)ベンズアミド、
N−(2−ヒドロキシエチル)−4−〔(2E,6E)
−3,7,11−トリメチル−2,6,10−ドデカト
リエニルオキシ〕ベンズアミド、N,N−ジメチル−4
−〔(2E,6E)−3,7,11−トリメチル−2,
6,10−ドデカトリエニルオキシ〕ベンズアミド等が
挙げられる。Preferred examples of the benzoic acid amide derivative represented by the general formula (1) include 4-[(2E,
6E) -3,7,11-trimethyl-2,6,10-dodecatrienyloxy] benzamide, 4- (12-hydroxydodecyloxy) benzamide, 4- (12-
Hydroxyoctadecyloxy) benzamide, 4-
(11-hydroxyundecyloxy) benzamide,
4- (10-hydroxydecyloxy) benzamide,
N- (2-hydroxyethyl) -4-[(2E, 6E)
-3,7,11-Trimethyl-2,6,10-dodecatrienyloxy] benzamide, N, N-dimethyl-4
-[(2E, 6E) -3,7,11-trimethyl-2,
6,10-dodecatrienyloxy] benzamide and the like can be mentioned.
【0019】安息香酸アミド誘導体(1)又はその塩
は、例えば次の反応式1又は2に従って製造することが
できる。The benzoic acid amide derivative (1) or a salt thereof can be produced, for example, according to the following reaction scheme 1 or 2.
【0020】[0020]
【化3】 Embedded image
【0021】〔式中、Yはハロゲン原子、p−トルエン
スルホニル基、メタンスルホニル基等の脱離基を示し、
R1 、R2 及びR3 は前記と同じ〕[In the formula, Y represents a leaving group such as a halogen atom, p-toluenesulfonyl group, methanesulfonyl group,
R 1 , R 2 and R 3 are the same as above]
【0022】すなわち、化合物(2)に化合物(3)を
反応させることにより、安息香酸アミド誘導体(1)が
製造される。That is, the benzoic acid amide derivative (1) is produced by reacting the compound (2) with the compound (3).
【0023】この反応は、1モルの化合物(2)に対し
て0.5〜3.0モルの化合物(3)を用い、通常0〜
150℃、好ましくは20〜100℃の温度にて数時間
攪拌することにより行うのが好ましい。この反応は塩基
の存在下に行うのが好ましく、当該塩基としては、反応
に悪影響を及ぼさなければ如何なるものでも用いうる
が、例えば水素化ナトリウム、炭酸カリウム、水酸化ナ
トリウム、水酸化カリウム、炭酸ナトリウム等が好適に
用いられる。In this reaction, 0.5 to 3.0 mol of the compound (3) is used per 1 mol of the compound (2), and usually 0 to
It is preferably carried out by stirring at a temperature of 150 ° C., preferably 20 to 100 ° C. for several hours. This reaction is preferably carried out in the presence of a base, and any base can be used as long as it does not adversely affect the reaction. For example, sodium hydride, potassium carbonate, sodium hydroxide, potassium hydroxide, sodium carbonate. Etc. are preferably used.
【0024】また、上記反応に用いることができる溶媒
としては、反応に不活性なものであれば如何なるもので
もよいが、例えば、N,N−ジメチルホルムアミド、ジ
メチルスルホキシド、テトラヒドロフラン、エタノー
ル、メタノール、アセトン等が好適である。反応終了
後、溶媒を留去し、クロマトグラフィー、再結晶等の手
段で精製することにより、上記安息香酸アミド誘導体
(1)が単離できる。Any solvent can be used in the above reaction as long as it is inert to the reaction. For example, N, N-dimethylformamide, dimethylsulfoxide, tetrahydrofuran, ethanol, methanol, acetone. Etc. are suitable. After completion of the reaction, the solvent is distilled off, and the benzoic acid amide derivative (1) can be isolated by purification by means such as chromatography and recrystallization.
【0025】[0025]
【化4】 [Chemical 4]
【0026】〔式中、R1 、R2 及びR3 は前記と同
じ〕[Wherein R 1 , R 2 and R 3 are the same as above]
【0027】すなわち、化合物(4)を塩化チオニル等
の酸ハロゲン化剤で処理した後、塩基の存在下、アミン
類と反応させることにより、安息香酸アミド誘導体
(1)を製造することができる。That is, the benzoic acid amide derivative (1) can be produced by treating the compound (4) with an acid halogenating agent such as thionyl chloride and then reacting it with an amine in the presence of a base.
【0028】化合物(4)と酸ハロゲン化剤との反応
は、例えばテトラヒドロフラン、ジエチルエーテル、メ
チルクロライド、N,N−ジメチルホルムアミド、ジメ
チルスルホキシド等の溶媒中化合物(4)に酸ハロゲン
化剤を加えて0〜100℃の温度で攪拌することにより
行われる。このようにして得られた酸ハロゲン化物とア
ミン類との反応は、例えば水酸化ナトリウム、水酸化カ
リウム、炭酸ナトリウム等の塩基の存在下、−20〜1
00℃の温度で攪拌することにより行われる。The reaction between the compound (4) and the acid halogenating agent is carried out by adding the acid halogenating agent to the compound (4) in a solvent such as tetrahydrofuran, diethyl ether, methyl chloride, N, N-dimethylformamide, dimethylsulfoxide and the like. And stirring at a temperature of 0 to 100 ° C. The reaction between the acid halide thus obtained and the amines is carried out in the presence of a base such as sodium hydroxide, potassium hydroxide or sodium carbonate at −20 to 1
It is carried out by stirring at a temperature of 00 ° C.
【0029】得られた安息香酸アミド誘導体(1)は、
常法に従い前記の塩に変換することができる。The obtained benzoic acid amide derivative (1) is
It can be converted into the above-mentioned salt according to a conventional method.
【0030】かくして得られた安息香酸アミド誘導体
(1)又はその塩は、ヒト皮膚の線維芽細胞のコラーゲ
ン合成を顕著に促進させる作用を有し、かつしわを改善
する作用を有するので、皮膚化粧料等の皮膚外用剤の有
効成分として使用できる。The thus-obtained benzoic acid amide derivative (1) or a salt thereof has an action of significantly promoting collagen synthesis of fibroblasts of human skin and an action of improving wrinkles, and therefore skin makeup It can be used as an active ingredient of external preparations for skin such as cosmetics.
【0031】[0031]
【実施例】次に実施例を挙げて本発明を更に詳細に説明
するが、本発明はこれら実施例に何ら限定されるもので
はない。The present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
【0032】実施例1 10mlの滴下ロートを備えた100mlナフフラスコに、
4−ヒドロキシベンズアミド2.00g(14.6mmo
l)、炭酸カリウム2.42g(17.5mmol)、N,
N−ジメチルホルムアミド15mlを入れ、室温下攪拌し
ながら、ファルネシルクロリド7.03g(29.2mm
ol)を10分間かけて滴下した。滴下後、80℃に加温
し、3時間攪拌した。希塩酸300ml中にあけ、酢酸エ
チルで抽出した。水100ml、飽和食塩水200mlで洗
浄した後、無水硫酸ナトリウムで乾燥した。濾過後、減
圧濃縮して得られる粗生成物をシリカゲルクロマトグラ
フィーにて精製して4−〔(2E,6E)−3,7,1
1−トリメチル−2,6,10−ドデカトリエニル〕ベ
ンズアミド3.09g(収率62%)を得た。分析結果
を以下に示す。Example 1 In a 100 ml Nuff flask equipped with a 10 ml dropping funnel,
4-hydroxybenzamide 2.00 g (14.6 mmo
l), potassium carbonate 2.42 g (17.5 mmol), N,
Add 15 ml of N-dimethylformamide, and stir at room temperature while stirring farnesyl chloride 7.03 g (29.2 mm).
ol) was added dropwise over 10 minutes. After dropping, the mixture was heated to 80 ° C. and stirred for 3 hours. It was poured into 300 ml of diluted hydrochloric acid and extracted with ethyl acetate. The extract was washed with 100 ml of water and 200 ml of saturated saline and then dried over anhydrous sodium sulfate. After filtration, the crude product obtained by concentration under reduced pressure is purified by silica gel chromatography to give 4-[(2E, 6E) -3,7,1.
3.09 g (yield 62%) of 1-trimethyl-2,6,10-dodecatrienyl] benzamide was obtained. The analysis results are shown below.
【0033】形状:無色個体 融点:76.5〜77.7℃1 H−NMR(CDCl3 ,ppm) 1.60〜1.75(m,12H),2.00〜2.1
6(m,8H),4.59(d,2H,J=6.5H
z),4.98〜5.22(m,2H),5.48
(t,1H,J=6.3Hz),5.79(brs,2
H),6.94(d,2H,J=8.8Hz),7.7
7(d,2H,J=8.8Hz). IR(KBr,cm-1) 3404,3176,2924,1648,1620,
1426,1398,1254.Form: colorless solid Melting point: 76.5 to 77.7 ° C. 1 H-NMR (CDCl 3 , ppm) 1.60 to 1.75 (m, 12H), 2.00 to 2.1
6 (m, 8H), 4.59 (d, 2H, J = 6.5H
z), 4.98 to 5.22 (m, 2H), 5.48
(T, 1H, J = 6.3 Hz), 5.79 (brs, 2
H), 6.94 (d, 2H, J = 8.8 Hz), 7.7
7 (d, 2H, J = 8.8 Hz). IR (KBr, cm -1 ) 3404, 3176, 2924, 1648, 1620,
1426, 1398, 1254.
【0034】実施例2 実施例1において、ファルネシルクロリドの代わりに1
2−ブロモドデカノールを用いて、4−(12−ヒドロ
キシドデシルオキシ)ベンズアミドを合成した。Example 2 In Example 1, 1 was used instead of farnesyl chloride.
4- (12-Hydroxydodecyloxy) benzamide was synthesized using 2-bromododecanol.
【0035】形状:無色個体 融点:141.4〜142.1℃1 H−NMR(CD3OD,ppm) 1.66〜1.90(m,20H),3.52(t,2
H,J=6.5Hz),4.02(t,2H,J=6.
4Hz),6.81(d,2H,J=8.9Hz),
7.82(d,2H,J=8.9Hz). IR(KBr,cm-1) 3436,3316,3204,2924,2856,
1648,1620,1424,1400,1256.Form: colorless solid Melting point: 141.4 to 142.1 ° C. 1 H-NMR (CD 3 OD, ppm) 1.66 to 1.90 (m, 20H), 3.52 (t, 2)
H, J = 6.5 Hz), 4.02 (t, 2H, J = 6.
4 Hz), 6.81 (d, 2H, J = 8.9 Hz),
7.82 (d, 2H, J = 8.9 Hz). IR (KBr, cm -1 ) 3436, 3316, 3204, 2924, 2856,
1648, 1620, 1424, 1400, 1256.
【0036】試験例1 コラーゲン合成促進効果 コンフルエントにまで培養した、ヒト皮膚線維芽細胞
(5%FCS(牛胎児血清)含有変性ダルベッコ・エッ
センシャル培地:以下DMEMと略す)を、0.5%F
CS含有DMEMに換え、これに被検化合物を1μM〜
10μMの濃度になるように添加し、37℃で24時間
培養した。その後トリチウムラベル化されたプロリン(
3H−プロリン)を加え(5μCi/ml培地)、更に2
7℃で培養をつづけ、3H−プロリンをとり込ませた。
24時間後培地を回収し、培地中に含まれる3H−ラベ
ル化コラーゲンの量をコラーゲンの精製を行い定量した
(D.F.Webster,W.Harvey.,An
alytical.Biochem.96,220(1
979))。結果を表1に示す。その結果、安息香酸ア
ミド誘導体(1)はヒト皮膚線維芽細胞におけるコラー
ゲン合成を顕著に促進することが判明した。Test Example 1 Collagen synthesis promoting effect Human skin fibroblasts (denatured Dulbecco's essential medium containing 5% FCS (fetal calf serum): abbreviated as DMEM hereinafter) 0.5% F were cultured to confluence.
The test compound was replaced with CS-containing DMEM and 1 μM to
It was added so as to have a concentration of 10 µM and cultured at 37 ° C for 24 hours. Then triline-labeled proline (
3 H-proline) was added (5 μCi / ml medium), and then 2
The culture was continued at 7 ° C. to incorporate 3 H-proline.
After 24 hours, the medium was collected, and the amount of 3 H-labeled collagen contained in the medium was quantified by purifying collagen (DF Webster, W. Harvey., An.
analytical. Biochem. 96 , 220 (1
979)). The results are shown in Table 1. As a result, it was found that the benzoic acid amide derivative (1) significantly promotes collagen synthesis in human skin fibroblasts.
【0037】[0037]
【表1】 [Table 1]
【0038】化合物1:4−{(2E,6E)−3,
7,11−トリメチル−2,6,10−ドデカトリエニ
ルオキシ}ベンズアミド 化合物2:4−(12−ヒドロキシドデシルオキシ)ベ
ンズアミドCompound 1: 4-{(2E, 6E) -3,
7,11-Trimethyl-2,6,10-dodecatrienyloxy} benzamide Compound 2: 4- (12-hydroxydodecyloxy) benzamide
【0039】試験例2 UVB照射によりヘアレスマウスに生成したしわへの安
息香酸アミド誘導体(1)の作用: (a)ヘアレスマウス(HR/ICR,実験開始時9週
齢)に、東芝健康線用ランプ20SEを6本使用してU
VB光を週3回照射した。エネルギー量はTOKYO
OPTICAL社製のUV−Radiometer U
VR−305/365Dを用いて測定した。1回の照射
量は1MED以下とし、0.28mW/cm2のエネルギー
量で65mJとした。照射期間は20週間で、ヘアレスマ
ウス背部にしわが形成されていることを確認した後、各
群8匹に分け、0.005%濃度の安息香酸アミド誘導
体(1)のエタノール溶液を80μlずつ週5回、6週
間塗布し続けた。コントロールとしてエタノールのみ8
0μlずつサンプル同様に塗布した。塗布終了後、しわ
の度合を肉眼により、下記の基準(しわ指数)で評価し
た。結果を表3に示す。Test Example 2 Action of Benzoic Acid Amide Derivative (1) on Wrinkles Produced in Hairless Mice by UVB Irradiation: (a) Hairless mice (HR / ICR, 9 weeks old at the start of experiment) U using 6 lamps 20SE
VB light was irradiated 3 times a week. The amount of energy is TOKYO
UV-Radiometer U made by OPTICAL
It measured using VR-305 / 365D. The irradiation amount per irradiation was 1 MED or less, and the energy amount was 0.28 mW / cm 2 and was 65 mJ. The irradiation period was 20 weeks, and after confirming that a wrinkle was formed on the back of the hairless mouse, each group was divided into 8 mice, and 80 μl of a 0.005% concentration benzoic acid amide derivative (1) ethanol solution was added 5 times a week. One application was continued for 6 weeks. Only ethanol as a control 8
Each 0 μl was applied in the same manner as the sample. After the application, the degree of wrinkles was evaluated with the naked eye according to the following criteria (wrinkle index). The results are shown in Table 3.
【0040】[0040]
【表2】(しわ指数) 1:しわが完全に消滅 2:しわがあるのかないのかわからない 3:しわが少しある 4:しわが非常にある[Table 2] (Wrinkle index) 1: Wrinkles disappear completely 2: Do not know if there are wrinkles 3: Wrinkles are a little 4: Wrinkles are very
【0041】(b)更に、しわの詳細を解析するため、
被検化合物塗布0週時(塗布日)と6週時に各マウスに
ついて、ハイドロフィリック エクザフレックス親水性
ビニルシリコーン印象材を用いて、皮膚のレプリカを直
径1cm2 の大きさで3ケ所から採取した。このレプリカ
を水平状態にして30度方向から光を照射し、しわによ
ってできる陰の割合を画像解析装置を用いて面積率
(%)として求めた。次に、塗布0週時に対する6週時
のしわ改善率を以下の式で求めた。(B) Furthermore, in order to analyze the details of wrinkles,
At 0 week (application day) and 6 weeks after application of the test compound, a replica of skin was collected from 3 sites with a diameter of 1 cm 2 on each mouse using Hydrophilic Exaflex hydrophilic vinyl silicone impression material. . This replica was placed in a horizontal state and irradiated with light from the direction of 30 degrees, and the ratio of shadows formed by wrinkles was obtained as an area ratio (%) using an image analyzer. Next, the wrinkle improvement rate at 6 weeks with respect to 0 weeks after application was determined by the following formula.
【0042】[0042]
【数1】 [Equation 1]
【0043】結果を表3に示す。この結果、安息香酸ア
ミド誘導体(1)を塗布することにより、ヘアレスマウ
ス背部に生成したしわを消滅/改善させることができる
ことが判明した。The results are shown in Table 3. As a result, it was found that the wrinkles formed on the back of the hairless mouse can be eliminated / improved by applying the benzoic acid amide derivative (1).
【0044】[0044]
【表3】 [Table 3]
【0045】[0045]
【発明の効果】安息香酸アミド誘導体(1)又はその塩
はヒト皮膚の真皮に存在する線維芽細胞のコラーゲン合
成を促進させ、その結果、加齢や紫外線照射によって生
じるしわを改善するので皮膚外用剤として有用である。EFFECTS OF THE INVENTION The benzoic acid amide derivative (1) or a salt thereof promotes collagen synthesis of fibroblasts existing in the dermis of human skin, and as a result, improves wrinkles caused by aging and UV irradiation. It is useful as an agent.
─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成6年12月12日[Submission date] December 12, 1994
【手続補正1】[Procedure Amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】0025[Name of item to be corrected] 0025
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【0025】[0025]
【化4】 [Chemical 4]
───────────────────────────────────────────────────── フロントページの続き (72)発明者 藤村 努 栃木県河内郡上三川町上蒲生2166 (72)発明者 武馬 吉則 栃木県河内郡南河内町祇園5−26−6 ─────────────────────────────────────────────────── ─── Continued Front Page (72) Inventor Tsutomu Fujimura 2166 Kamigamo, Kamimikawa-cho, Kawachi-gun, Tochigi Prefecture (166) Inventor Yoshinori Takema 5-26-6 Gion Minamikochi-cho, Kawachi-gun, Tochigi Prefecture
Claims (1)
又は3,7,11−トリメチル−2,6,10−ドデカ
トリエニル基を示し、R2 及びR3 はそれぞれ水素原子
又は水酸基が置換していてもよい炭素数1〜3のアルキ
ル基を示す〕で表わされる安息香酸アミド誘導体又はそ
の塩。1. A compound represented by the general formula (1): [In the formula, R 1 represents a hydroxyalkyl group having 8 to 24 carbon atoms or a 3,7,11-trimethyl-2,6,10-dodecatrienyl group, and R 2 and R 3 each represent a hydrogen atom or a hydroxyl group. Represents an optionally substituted alkyl group having 1 to 3 carbon atoms] or a salt thereof.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30486994A JPH08157436A (en) | 1994-12-08 | 1994-12-08 | Benzoic acid amide derivative |
| PCT/JP1995/002498 WO1996017589A1 (en) | 1994-12-08 | 1995-12-06 | Method of smoothing or removing wrinkles and method of stimulating collagen synthesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30486994A JPH08157436A (en) | 1994-12-08 | 1994-12-08 | Benzoic acid amide derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH08157436A true JPH08157436A (en) | 1996-06-18 |
Family
ID=17938262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30486994A Pending JPH08157436A (en) | 1994-12-08 | 1994-12-08 | Benzoic acid amide derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH08157436A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014181210A (en) * | 2013-03-19 | 2014-09-29 | Ueno Fine Chem Ind Ltd | Epidermal keratinocyte proliferation promoter containing salicylic acid derivative |
| CN112190515A (en) * | 2019-07-08 | 2021-01-08 | 大江生医股份有限公司 | Black rice extracted fermented product and preparation and application thereof |
-
1994
- 1994-12-08 JP JP30486994A patent/JPH08157436A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014181210A (en) * | 2013-03-19 | 2014-09-29 | Ueno Fine Chem Ind Ltd | Epidermal keratinocyte proliferation promoter containing salicylic acid derivative |
| CN112190515A (en) * | 2019-07-08 | 2021-01-08 | 大江生医股份有限公司 | Black rice extracted fermented product and preparation and application thereof |
| CN112190515B (en) * | 2019-07-08 | 2023-06-27 | 大江生医股份有限公司 | Black rice extraction ferment, preparation and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1963250B1 (en) | Biphenyl derivatives as selective agonists of gamma rar receptor | |
| CN114829365A (en) | Thiazololactam compounds as ERK inhibitors and application thereof | |
| US7452878B2 (en) | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | |
| BG105954A (en) | Oxamic acids and derivatives as thyroid receptor ligands | |
| US20090012129A1 (en) | Novel biaromatic compounds that modulate ppar-receptors | |
| JPH0920655A (en) | Retinoid type compound and pharmaceutical and cosmetic composition containing the same | |
| US6916844B2 (en) | Hydroxy pyranone derivative and preparation method thereof | |
| FR2880020A1 (en) | NEW MODULATORY LIGANDS OF RAR RECEPTORS, USE IN HUMAN MEDICINE AND COSMETICS | |
| JP2901577B2 (en) | Novel heterocyclic biaryl compounds and their use in medical or veterinary medicine and cosmetics | |
| SK282757B6 (en) | New [(3-alkoxy-phenoxy)-ethyl]-dialkylamine derivatives and their use as local anaesthetics | |
| JPH08157436A (en) | Benzoic acid amide derivative | |
| Oomori et al. | Structure of a new sulfur-containing amino acid | |
| WO1996017589A1 (en) | Method of smoothing or removing wrinkles and method of stimulating collagen synthesis | |
| KR100629712B1 (en) | Hydroxamic acid derivative having anti-aging activity and preparation method thereof | |
| US20100035988A1 (en) | Methods for activating PPAR gamma-type receptors | |
| EP1680395B1 (en) | Novel ligand activating rar receptors used in human medicine and cosmetics | |
| FR2678269A1 (en) | 1-(4-Chlorophenyl)-2-[4-(2-phenylethyl)piperid-1-yl]ethanol derivatives, their preparation and their application in therapeutics | |
| JPH06145123A (en) | Amide derivative, intermediate for producing the same, and external preparation for skin containing the amide derivative | |
| JP4784725B2 (en) | Maillard reaction inhibitor | |
| EP1742608B1 (en) | Biaromatic compounds which activate ppar(gamma) type receptors, their process of preparation and their use in cosmetic or pharmaceutical compositions | |
| JP4631463B2 (en) | Novel carnosine ester compounds | |
| JPH08208463A (en) | Collagen synthesis promoter | |
| JP4939941B2 (en) | Hydroxamic acid derivative and method for producing the same | |
| JP2000178163A (en) | External preparation for skin | |
| KR100704468B1 (en) | Hydroxy pyranone derivative and preparation method thereof |